Whole grain-rich diet reduces body weight and systemic low-grade inflammation without inducing major changes of the gut microbiome: a randomised cross-over trial

Objective To investigate whether a whole grain diet alters the gut microbiome and insulin sensitivity, as well as biomarkers of metabolic health and gut functionality. Design 60 Danish adults at risk of developing metabolic syndrome were included in a randomised cross-over trial with two 8-week dietary intervention periods comprising whole grain diet and refined grain diet, separated by a washout period of ≥6 weeks. The response to the interventions on the gut microbiome composition and insulin sensitivity as well on measures of glucose and lipid metabolism, gut functionality, inflammatory markers, anthropometry and urine metabolomics were assessed. Results 50 participants completed both periods with a whole grain intake of 179±50 g/day and 13±10 g/day in the whole grain and refined grain period, respectively. Compliance was confirmed by a difference in plasma alkylresorcinols (p<0.0001). Compared with refined grain, whole grain did not significantly alter glucose homeostasis and did not induce major changes in the faecal microbiome. Also, breath hydrogen levels, plasma short-chain fatty acids, intestinal integrity and intestinal transit time were not affected. The whole grain diet did, however, compared with the refined grain diet, decrease body weight (p<0.0001), serum inflammatory markers, interleukin (IL)-6 (p=0.009) and C-reactive protein (p=0.003). The reduction in body weight was consistent with a reduction in energy intake, and IL-6 reduction was associated with the amount of whole grain consumed, in particular with intake of rye. Conclusion Compared with refined grain diet, whole grain diet did not alter insulin sensitivity and gut microbiome but reduced body weight and systemic low-grade inflammation

Platform trials

Platform trials focus on the perpetual testing of many interventions in a disease or a setting. These trials have lasting organizational, administrative, data, analytic, and operational frameworks making them highly efficient. The use of adaptation often increases the probabilities of allocating participants to better interventions and obtaining conclusive results. The COVID-19 pandemic showed the potential of platform trials as a fast and valid way to improved treatments. This review gives an overview of key concepts and elements using the Intensive Care Platform Trial (INCEPT) as an example.</p

Marine chemical contaminants – support to the harmonization of MSFD D8 methodological standards: Matrices and threshold values/reference levels for relevant substances

According to the Article 17(2) of the Marine Strategy Framework Directive (MSFD), Member States have to review and update their marine strategies every six years. This requires updates of the MSFD Articles 8, 9 and 10 by 2018. The current report provides an overview of the substances, matrices and threshold values that Member States intend to use for the assessment of the Descriptor 8 in this MSFD reporting cycle. This compilation aims at evaluating gaps and discrepancies between Member States and identifying aspects that need further harmonization. It also helps understand which issues should be addressed to achieve consistency with the new MSFD Commission Decision (EU 2017/848). The information has been gathered from the contributions of the MSFD Expert Network on Contaminants, an informal network established to support MSFD implementation. This work is part of a process to help regulators to assess relevant contaminants in their jurisdictional area, thus aiming at EU national authorities but also at Regional Sea Conventions in the shared marine basins.JRC.D.2-Water and Marine Resource